TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26576858

Group type: EXPERIMENTAL
Intervention: Betahistine 18 mg plus ondansetron 4 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Ondansetron 4 mg alone (placebo group)
Number of subjects: 168
Study: 25348459

Group type: EXPERIMENTAL
Intervention: Male partner involvement plus a behavioral PMTCT intervention
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Control group (women attending without their male partners)
Number of subjects: 1440
Study: 23285780

Group type: EXPERIMENTAL
Intervention: Ketac Molar Aplicap glass-ionomer material
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (tooth enamel)
Number of subjects: 15
Study: 20517680

Group type: EXPERIMENTAL
Intervention: Platelet-derived growth factors (platelet-leukocyte gel)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no platelet-derived growth factors)
Number of subjects: 50
Study: 18528405

Group type: EXPERIMENTAL
Intervention: Fermented lactotripeptides (LTPs)-containing milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15882481

Group type: EXPERIMENTAL
Intervention: Web-based educational module promoting size acceptance
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 258
Study: 14587556

Group type: EXPERIMENTAL
Intervention: Large-scale ensemble averaging of ambulatory impedance cardiograms
Number of subjects: 21

Group type: COMPARATOR
Intervention: Classical 60-sec ensemble averages
Number of subjects: 21
Study: 10918098

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg intravenously)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Promethazine (25 mg intravenously)
Number of subjects: 84
Study: 9014166

Group type: EXPERIMENTAL
Intervention: Stimulation of the dominant eye (left or right)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Stimulation of the non-dominant eye
Number of subjects: 26
Study: 1561474

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 45
Study: 3886303

Group type: EXPERIMENTAL
Intervention: 200 mg tiaprofenic acid 3-times daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30527259

Group type: EXPERIMENTAL
Intervention: Cottonseed oil (CSO) diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Olive oil (OO) diet
Number of subjects: 15
Study: 26250967

Group type: EXPERIMENTAL
Intervention: Early egg introduction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24628859

Group type: COMPARATOR
Intervention: Patients reporting no angina symptoms (n=28)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Patients reporting monthly angina (n=188)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Patients reporting weekly angina (n=283)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Patients reporting daily angina (n=49)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Patients improving ≥1 SAQAF classification (n=254/541, 47%)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Patients improving ≥20 points on the SAQAF (n=355/541, 66%)
Number of subjects: 548
Study: 22458918

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%-timolol 0.5%
Number of subjects: 148

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 148
Study: 20035174

Group type: EXPERIMENTAL
Intervention: Minimally invasive medial plating using hybrid locking and nonlocking techniques
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study: 17881928

Group type: EXPERIMENTAL
Intervention: Prethickened formula (AR)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Regular formula (R)
Number of subjects: 74
Study: 15901241

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nicorandil (an agonist of KATP channels)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IP pretreated with glibenclamide (an antagonist of KATP channels)
Number of subjects: 36
Study: 12020982

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9882035

Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) administered to patients with dyspepsia
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) for test-retest reliability
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) for inter-rater reliability
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Leeds Dyspepsia Questionnaire (LDQ) before and after therapy
Number of subjects: 314
Study: 7927617

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 6 and 14 weeks (group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 1 and 2 months (group B)
Number of subjects: 39
Study: 3286327

Group type: EXPERIMENTAL
Intervention: Human proinsulin (HPI)
Number of subjects: 114

Group type: COMPARATOR
Intervention: rDNA human insulin (HI)
Number of subjects: 114
Study: 29077864

Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Grazoprevir/Elbasvir + Ribavirin for 16 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Grazoprevir/Elbasvir + Ribavirin for 24 weeks
Number of subjects: 26
Study: 27098193

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2800 IU)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 24958656

Group type: EXPERIMENTAL
Intervention: Aerobic-training (AT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Strength-training (ST)
Number of subjects: 46
Study: 24228531

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine combined HAART
Number of subjects: 37

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 37
Study: 21642064

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) combined with conventional physical therapy (24 1-hour sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physical therapy (24 1-hour sessions)
Number of subjects: 20
Study: 19564366

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (80/480 mg) twice daily for 3 days
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Predictive modeling suggests a twice-daily regimen for 5 days would be preferable in later pregnancy
Number of subjects: 103
Study: 17058041

Group type: EXPERIMENTAL
Intervention: High TMS stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low TMS stimulation
Number of subjects: 42
Study: 15318468

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 11511127

Group type: EXPERIMENTAL
Intervention: Cognitive averaging task with varying liquid volumes (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive averaging task with varying liquid volumes (Experiment 2)
Number of subjects: 0
Study: 11229183

Group type: EXPERIMENTAL
Intervention: Early haemodialysis (Group B)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conservative treatment (Group A)
Number of subjects: 35
Study: 8280547

Group type: EXPERIMENTAL
Intervention: i.v. pethidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rectal pethidine
Number of subjects: 20
Study: 6695297

Group type: EXPERIMENTAL
Intervention: 60 mg diazoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg diazoxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 300 mg diazoxide
Number of subjects: 0
Study: 31121104

Group type: EXPERIMENTAL
Intervention: Cx601 (darvadstrocel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 0
Study: 30409170

Group type: EXPERIMENTAL
Intervention: Daily mobilisation in a tilt table with an integrated stepping device (ERIGO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 26248565

Group type: EXPERIMENTAL
Intervention: Dairy supplementation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nondairy isocaloric and isoprotein supplement
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 26
Study: 25440373

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acupuncture plus stretching
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo laser acupuncture
Number of subjects: 19
Study: 22878686

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.20% ropivacaine (Group R)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No injection (Group C)
Number of subjects: 124
Study: 20728318

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 17663105

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (anti-infection, inhibiting secretion of pancreas, improving microcirculation, protective agent of gastric mucosa)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 17288334

Group type: COMPARATOR
Intervention: RelyX ARC-Single Bond (Group I C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Duo Link-One Step (Group II C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RelyX Temp NE (Groups I ND and II ND)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RelyX Temp E (Groups I ED and II ED)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RelyX NE (Groups I N and II N)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RelyX E (Groups I E and II E)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dual bonding technique (Groups I ND and ED, II ND and ED)
Number of subjects: 100
Study: 15229064

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11155965

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCAs plus lithium, monoamine oxidase inhibitors (MAOIs), or electroconvulsive therapy (ECT)
Number of subjects: 0
Study: 8923355

Group type: EXPERIMENTAL
Intervention: Recombinant human tumor necrosis factor receptor (p80) fusion protein (rhTNFR:Fc)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 22
Study: 1455983

Group type: EXPERIMENTAL
Intervention: Mexiletine (MXT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tocainide (TCD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 6697306

Group type: EXPERIMENTAL
Intervention: Regimen 2 (modified LSA2-L2)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Regimen 1 (COMP: modified cyclophosphamide, Oncorin, methotrexate, prednisone)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Regimen 1 (COMP)
Number of subjects: 256
Study: 30942014

Group type: EXPERIMENTAL
Intervention: Chicken‐claw needling at Shangbaxie (Extra) and Hegu (LI 4) combined with acupuncture at Houxi (SI 3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional acupuncture at the same points as the observation group
Number of subjects: 42
Study: 28664388

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) from admission (AD) to D+7
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (oral hygiene)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups (PBM and control)
Number of subjects: 51
Study: 26713987

Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 118
Study: 23167783

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg daily for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Folic acid 2.0 mg daily for 14 days (Control)
Number of subjects: 28
Study: 21663423

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19184217

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-soaked Tabotamp positioned in the gallbladder bed
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: bupivacaine infiltrated in the muscular fasciae of the trocars' seat
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not using local anesthetic)
Number of subjects: 45
Study: 16393430

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 994

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Rivastigmine and Donepezil
Number of subjects: 994
Study: 14510929

Group type: EXPERIMENTAL
Intervention: Topiramate (50 mg daily after titration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10732883

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 8884144

Group type: EXPERIMENTAL
Intervention: BCG Pasteur
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BCG RIV
Number of subjects: 106

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BCG-treated patients (both types)
Number of subjects: 106
Study: 1326721

Group type: EXPERIMENTAL
Intervention: Thymex L (100 mg 3 times a week, total dose 1800 mg, i.m.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy only (60 Gy in 30 fractions)
Number of subjects: 0
Study: 3919028

Group type: EXPERIMENTAL
Intervention: Diphosphonate
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo or no drug therapy (Control)
Number of subjects: 177
Study: 30764702

Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiac Rehabilitation (exercise plus education)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Exercise-only Cardiac Rehabilitation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 115
Study: 29512827

Group type: EXPERIMENTAL
Intervention: 170 μg LPP administered subcutaneously over 3 weeks
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 26694502

Group type: EXPERIMENTAL
Intervention: Ball handle with the cable between the index and middle fingers (BallIM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ball handle with the cable between the middle and ring fingers (BallMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard handle (StandH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ball handle conditions (BallIM and BallMR)
Number of subjects: 0
Study: 24606070

Group type: EXPERIMENTAL
Intervention: Testosterone gel (high or low physiological dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21908133

Group type: EXPERIMENTAL
Intervention: Rate and volume adjusted BVM (RVBVM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Volume marked BVM (VBVM)
Number of subjects: 52
Study: 20354566

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: ACEI/ARBs
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2627
Study: 17684894

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Physiologic saline (control)
Number of subjects: 6
Study: 16236939

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Medical therapy (MT)
Number of subjects: 78
Study: 11372586

Group type: EXPERIMENTAL
Intervention: Napsagatran (80 micrograms/min) + Warfarin (25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Napsagatran (80 micrograms/min)
Number of subjects: 12
Study: 9732921

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg and amoxicillin 1 g, both given twice daily for 2 weeks (OA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily, clarithromycin 500 mg twice daily, and metronidazole 400 mg twice daily for 1 week (OCM)
Number of subjects: 1000
Study: 7994673

Group type: EXPERIMENTAL
Intervention: Healon with 0.5% timolol drops postoperatively (12 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Healon with acetazolamide postoperatively (16 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healon only (12 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No viscoelastic (10 patients)
Number of subjects: 50
Study: 3141099

Group type: EXPERIMENTAL
Intervention: Insulin-glyburide combination therapy
Number of subjects: 64
Study: 31329507

Group type: COMPARATOR
Intervention: Complex decongestive physiotherapy (CDP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Complex decongestive physiotherapy (CDP) + Kinesio Taping (KT)
Number of subjects: 32
Study: 28974203

Group type: EXPERIMENTAL
Intervention: Cefazolin administered prior to skin incision
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Cefazolin administered after cord clamping
Number of subjects: 1106
Study: 25846340

Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Number of subjects: 52
Study: 22757968

Group type: EXPERIMENTAL
Intervention: External Qigong Therapy (EQT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham EQT
Number of subjects: 101
Study: 20838775

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DAMP (20 mg/70 kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo DAMP
Number of subjects: 10
Study: 19083679

Group type: EXPERIMENTAL
Intervention: Dellagrotte core-integration intervention over 2 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study: 16868151

Group type: EXPERIMENTAL
Intervention: Progesterone (P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Estradiol (E2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Estradiol (E2) + Progesterone (P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 40
Study: 12439626

Group type: EXPERIMENTAL
Intervention: Nefazodone (450 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo Nefazodone (0 mg/day)
Number of subjects: 7
Study: 10856143

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg combined with fluticasone 100 microg (combination product)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 356

Group type: COMPARATOR
Intervention: Fluticasone 100 microg
Number of subjects: 356
Study: 9146330

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 70

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diltiazem and Digoxin
Number of subjects: 70
Study: 7974906

Group type: EXPERIMENTAL
Intervention: Four cycles of EP (Etoposide and Cisplatin) for good-risk GCT patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus ifosfamide (VIP, VeIP) and high-dose carboplatin and etoposide with AUBMT for poor-risk GCT patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel in combination chemotherapy regimens
Number of subjects: 0
Study: 2836295

Group type: EXPERIMENTAL
Intervention: Assertive case management (ACM)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (eligible to receive all other aftercare services)
Number of subjects: 167
Study: 30852432

Group type: EXPERIMENTAL
Intervention: Intervention teaching about psychology of burnout, stress, coping with patient death, and managing distress
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 227
Study: 28342911

Group type: EXPERIMENTAL
Intervention: Acute anaphylaxis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Peanut-induced allergic reactions
Number of subjects: 31
Study: 27312330

Group type: EXPERIMENTAL
Intervention: Small reamer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bone chisel
Number of subjects: 100
Study: 24178907

Group type: EXPERIMENTAL
Intervention: HILT plus exercise (HILT + EX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo laser plus exercise (PL + EX)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HILT alone
Number of subjects: 72
Study: 21963761

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) applied to the unlesioned pharyngeal cortex
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) applied to the unaffected pharyngeal cortex in patients with chronic dysphagia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham PAS
Number of subjects: 18
Study: 20506785

Group type: EXPERIMENTAL
Intervention: Creation of pleural tent (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pleural tent (group 2)
Number of subjects: 60
Study: 17643436

Group type: EXPERIMENTAL
Intervention: PHOPDT (Photodynamic therapy with Photofrin)
Number of subjects: 208

Group type: COMPARATOR
Intervention: OM (Omeprazole only)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: PHOPDT
Number of subjects: 208

Group type: COMPARATOR
Intervention: OM
Number of subjects: 208